Amanda King‐Ahmad

502 total citations
14 papers, 243 citations indexed

About

Amanda King‐Ahmad is a scholar working on Oncology, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Amanda King‐Ahmad has authored 14 papers receiving a total of 243 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Pharmacology and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Amanda King‐Ahmad's work include Drug Transport and Resistance Mechanisms (8 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Amanda King‐Ahmad is often cited by papers focused on Drug Transport and Resistance Mechanisms (8 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Amanda King‐Ahmad collaborates with scholars based in United States, South Korea and Finland. Amanda King‐Ahmad's co-authors include A. David Rodrigues, Ragu Ramanathan, Christopher L. Holliman, Manoli Vourvahis, Emi Kimoto, Brian Rago, Linda S. Wood, Mary Ellen Banker, Kevin Sweeney and Daiki Mori and has published in prestigious journals such as Pharmaceutical Research, Journal of Pharmaceutical Sciences and Clinical Pharmacology & Therapeutics.

In The Last Decade

Amanda King‐Ahmad

14 papers receiving 238 citations

Peers

Countries citing papers authored by Amanda King‐Ahmad

Since Specialization

Citations

This map shows the geographic impact of Amanda King‐Ahmad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda King‐Ahmad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda King‐Ahmad more than expected).

Fields of papers citing papers by Amanda King‐Ahmad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amanda King‐Ahmad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda King‐Ahmad. The network helps show where Amanda King‐Ahmad may publish in the future.

Co-authorship network of co-authors of Amanda King‐Ahmad

This figure shows the co-authorship network connecting the top 25 collaborators of Amanda King‐Ahmad. A scholar is included among the top collaborators of Amanda King‐Ahmad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amanda King‐Ahmad. Amanda King‐Ahmad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay 2024 ·Clinical Pharmacology & Therapeutics ·Yi‐An Bi, (unknown), Amanda King‐Ahmad, Mark A. West, Manthena V. S. Varma	5
2	Low Molecular Weight Acids and Organic Anion Transporting Polypeptide (OATP1B)-Mediated Hepatic Clearance: In Vitro and In Vivo Evaluation Using Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (Dustats) 2024 ·Drug Metabolism and Disposition ·Yi‐An Bi, (unknown), Amanda King‐Ahmad, Mark A. West, Emi Yamaguchi, Sangwoo Ryu, Sumathy Mathialagan, David A. Tess, Manthena V. S. Varma	1
3	Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity 2023 ·Pharmaceutical Research ·(unknown), Anna Plotka, (unknown), Julia Kaplan, (unknown), (unknown), Vivek S. Purohit, Martin E. Dowty, Robert Wołk, Manoli Vourvahis, Amanda King‐Ahmad, Sumathy Mathialagan, Mark A. West, Sarah Lazzaro, Sangwoo Ryu, A. David Rodrigues	3
4	Characterization of Bile Acid Sulfate Conjugates as Substrates of Human Organic Anion Transporting Polypeptides 2023 ·Molecular Pharmaceutics ·Christine C. Orozco, Mikko Neuvonen, Yi‐An Bi, Matthew A. Cerny, Sumathy Mathialagan, Laurie Tylaska, Brian Rago, Chester Costales, Amanda King‐Ahmad, Mikko Niemi, A. David Rodrigues	9
5	Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans 2022 ·Xenobiotica ·Tim F. Ryder, Arthur Bergman, Amanda King‐Ahmad, Neeta B. Amin, Manjinder S. Lall, T. Eric Ballard, Amit S. Kalgutkar	3
6	Effect of a Ketohexokinase Inhibitor (PF‐06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug 2022 ·Clinical Pharmacology & Therapeutics ·David A. Tess, Emi Kimoto, Amanda King‐Ahmad, Manoli Vourvahis, A. David Rodrigues, Arthur Bergman, (unknown), Veena Somayaji, Yan Weng, Kari R. Fonseca, John Litchfield, Manthena V. S. Varma	15
7	The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans 2022 ·Drug Metabolism and Disposition ·Jonathan Bauman, Angela C. Doran, Amanda King‐Ahmad, Raman Sharma, Gregory S. Walker, Jian Lin, Tsung H. Lin, Jean‐Baptiste Telliez, (unknown), Theunis C. Goosen, Christopher Banfield, Bimal Malhotra, Martin E. Dowty	24
8	An orthogonal methods assessment of topical drug concentrations in skin and the impact for risk assessment in the viable epidermis 2021 ·Regulatory Toxicology and Pharmacology ·Brett D. Hollingshead, Lindsay Tomlinson, (unknown), (unknown), (unknown), (unknown), Stacey R. Oppenheimer, Shawn P. O’Neil, Jessica L. Moore, Nathan Heath Patterson, (unknown), Jeremy L. Norris, Richard M. Caprioli, Kevin Beaumont, Amanda King‐Ahmad, (unknown), Jon C. Cook, Zaher A. Radi, Maik Schuler	3
9	Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs 2019 ·Clinical Pharmacology & Therapeutics ·Daiki Mori, Emi Kimoto, Brian Rago, Yusuke Kondo, Amanda King‐Ahmad, Ragu Ramanathan, Linda S. Wood, Jillian G. Johnson, Vu Le, Manoli Vourvahis, A. David Rodrigues, (unknown), Kenichi Furihata, Yuichi Sugiyama, Hiroyuki Kusuhara	77
10	A Sensitive Method for the Quantitation of the Peptide-Based Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Plasma Using Microfluidics Chromatography Tandem MS 2018 ·Bioanalysis ·Amanda King‐Ahmad, Amit S. Kalgutkar, Mark Niosi, Heather Eng, Christopher L. Holliman	5
11	A Fully Automated and Validated Human Plasma LC–MS/MS Assay for Endogenous OATP Biomarkers Coproporphyrin-I and Coproporphyrin-III 2018 ·Bioanalysis ·Amanda King‐Ahmad, (unknown), Ragu Ramanathan, Yanhua Zhang, (unknown), Yizhong Zhang, Christopher L. Holliman, A. David Rodrigues, (unknown)	24
12	A Highly Selective and Sensitive LC–MS/HRMS Assay for Quantifying Coproporphyrins as Organic Anion-Transporting Peptide Biomarkers 2017 ·Bioanalysis ·Ragu Ramanathan, Amanda King‐Ahmad, Christopher L. Holliman, A. David Rodrigues	19
13	In Vitro – In Vivo Extrapolation of Intestinal Availability for Carboxylesterase Substrates Using Portal Vein–Cannulated Monkey 2016 ·Journal of Pharmaceutical Sciences ·Patrick Trapa, Kevin Beaumont, Karen Atkinson, Heather Eng, Amanda King‐Ahmad, Dennis O. Scott, Tristan S. Maurer, Li Di	7
14	The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism 2011 ·Journal of Translational Medicine ·(unknown), Vaishali Sahasrabudhe, Kevin Sweeney, Meera Tugnait, Amanda King‐Ahmad, (unknown), Paula M. Loria, Mary Ellen Banker, David W. Piotrowski, Carine M. Boustany‐Kari	48

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact